Research Progress on Drugs Targeting PI3K in Anti-tumor Metastasis
Tumor metastasis is the primary cause of cancer lethality,accounting for approximately 90％of cancer-related deaths.The current clinical treatment methods for tumor metastasis are limited.Phosphatidylinositol-3-kinase(PI3K)signaling is one of the most important pathways in cells and plays a vital role in the occurrence,development and metastasis of tumors.Therefore,many pharmaceutical companies focus on development of PI3K inhibitors.Until now,five PI3K inhibitors have been approved by Food and Drug Administration(FDA)of USA,and more inhibitors are being studied in clinical trials.Many clinical trial results showed limited efficacy of PI3K inhibitors administered alone,therefore the combinations with other antitumor drugs are being tested.This article summarizes the PI3K signaling pathway and its role in the processes of tumor metastasis and also sorts out the new developments in the application of PI3K inhibitors alone or in combination with other drugs in tumor metastasis.It will provide a powerful reference for the further development and application of PI3K inhibitors.
万方数据
维普
